Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
|
|
UROLOGIX INC (ULGX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/12/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/17/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/25/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/23/2016 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 20% stake in Urologix Inc |
| 02/05/2016 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/01/2016 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 23.3% stake in Urologix Inc |
| 11/04/2015 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 23.3% stake in Urologix Inc |
| 07/10/2015 |
8-K
| Form 8-K - Current report |
| 07/07/2015 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 24.4% stake in Urologix Inc |
| 05/14/2015 |
10-Q
| Quarterly Report for the period ended March 31, 2015 |
| 05/13/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 03/23/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/13/2015 |
10-Q
| Quarterly Report for the period ended December 31, 2014 |
| 02/06/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Urologix, Inc. Statements of Operations Three Months Ended December 31, Six Months Ended December 31, 2014 2013 2014 2013 Sales $ 3,079 $ 3,806 $ 6,100 $ 7,585 Cost of goods sold 1,615 2,008 3,174 3,923 Gross profit 1,464 1,798 2,926 3,662 Costs and expenses: Sales and marketing 729 1,681 1,539 3,527 General and administrative 467 561 955 1,246 Research and development 337 452 671 874 Change in value of acquisition consideration — — Medical device tax 48 59 96 119 Amortization expense 17 22 40 44 Total costs and expenses 1,598 2,690 3,301 5,717 Operating loss Interest expense Foreign currency exchange gain/ 1 2 Loss before income taxes Income tax expense 4 16 9 28 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted average num..." |
|
| 01/28/2015 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 25.5% stake in Urologix Inc |
| 01/12/2015 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 01/09/2015 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 25.5% stake in Urologix Inc |
| 12/10/2014 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 27.2% stake in Urologix Inc |
| 11/13/2014 |
10-Q
| Quarterly Report for the period ended September 30, 2014 |
| 11/10/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/05/2014 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 09/25/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/23/2014 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/19/2014 |
10-K
| Annual Report for the period ended June 30, 2014 |
| 08/20/2014 |
8-K
| Quarterly results|
Docs:
|
"Urologix, Inc. Statements of Operations Three Months Ended June 30, Twelve Months Ended June 30, 2014 2013 2014 2013 Sales $ 3,294 $ 4,184 $ 14,235 $ 16,590 Cost of goods sold 1,711 2,279 8,142 8,407 Gross profit 1,583 1,905 6,093 8,183 Costs and expenses: Sales and marketing 1,011 2,080 5,850 7,719 General and administrative 526 421 2,299 2,515 Research and development 344 514 1,625 2,269 Change in value of acquisition consideration — Impairment of goodwill 3,036 — 3,036 — Gain on demutualization — — — Impairment of identifiable intangible assets — 160 — 160 Medical device tax 51 65 223 106 Amortization expense 23 26 95 104 Total costs and expenses 4,991 3,187 13,023 12,105 Operating loss Interest expense Gain on debt extinguishment — 206 — 206 Foreign currency exchange gain/ 2 Loss..." |
|
| 08/19/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/14/2014 |
10-Q
| Quarterly Report for the period ended March 31, 2014 |
| 05/07/2014 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended March 31, Nine Months Ended March 31, 2014 2013 2014 2013 Sales $ 3,356 $ 4,082 $ 10,941 $ 12,405 Cost of goods sold 2,507 2,056 6,431 6,127 Gross profit 849 2,026 4,510 6,278 Costs and expenses: Sales and marketing 1,313 1,915 4,839 5,639 General and administrative 527 711 1,773 2,094 Research and development 408 538 1,281 1,756 Change in value of acquisition consideration — Gain on demutualization — — Medical device tax 52 41 172 41 Amortization expense 28 26 72 78 Total costs and expenses 2,316 2,910 8,032 8,918 Operating loss Interest expense Foreign currency exchange gain/ 1 Loss before income taxes Income tax expense 18 17 46 48 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted average number of co..." |
|
| 04/16/2014 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits|
Docs:
|
"Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Third Quarter of Fiscal Year 2014 • Third quarter revenue totaled $3.4 million • Cash balance of $816 thousand as of March 31, 2014 MINNEAPOLIS — April 10, 2014— Urologix®, Inc. , the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a strategic restructuring of its organizational infrastructure and reported preliminary financial results for its fiscal year 2014 third quarter ended March 31, 2014. Strategic Restructuring of Organizational Infrastructure The strategic reorganization builds upon the Company’ s initiative, announced in the second quarter, to refocus the allocation of company resources and improve long-term profitability...." |
|
| 04/09/2014 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 28.4% stake in Urologix Inc |
| 03/27/2014 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 02/13/2014 |
10-Q
| Quarterly Report for the period ended December 31, 2013 |
| 02/13/2014 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 3.5% stake in UROLOGIX INC |
| 02/07/2014 |
SC 13D/A
| PERKINS CAPITAL MANAGEMENT INC reports a 29.7% stake in Urologix Inc |
|
|
|